

January 2, 2013



Q Therapeutics' CFO and Vice President of Corporate Development, Steve Borst, Featured on theStockRadio.com

SALT LAKE CITY, UT--(Marketwire - Jan 2, 2013) - **Q Therapeutics, Inc.**, an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, announced that *theStockRadio.com* has posted an audio interview conducted with the Company's CFO and Vice President of Corporate Development, Steve Borst.

To access the interview, please go to <http://thestockradio.com/cfo-steinen-borst-of-q-therapeutics-qcel/1914>.

theStockRadio.com is a small-cap research and investment commentary provider. *theStockRadio.com* strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. Moreover, *theStockRadio.com* provides investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on *theStockRadio.com*, please visit <http://thestockradio.com>.

theStockRadio.com Disclosure

theStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. theStockRadio.com is a Web site wholly owned by Allan James Group. Neither theStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, theStockRadio.com, for complete risks and disclosures. To contact theStockRadio.com, please send an email to info@theStockRadio.com.

About Q Therapeutics, Inc.

Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, *Q-Cells*[®], is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing

essential support functions that occur in healthy central nervous system tissues. *Q-Cells* may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2013. For more information, visit www.qthera.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Q Therapeutics' technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of its intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Q Therapeutics' periodic reports, including the quarterly report on Form 10-Q for the period ended September 30, 2012 and the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

FOR MORE INFORMATION:

Hanover|Elite
Dodi Handy or Kathy Addison
407-585-1080